Digitizing Alzheimer’s Disease Trial with eCOA and Digital Cognitive Assessments

Digital technologies are playing a critical role in transforming both how and what we measure in Alzheimer’s disease. Digital cognitive assessments (DGAs) are reshaping early detection and endpoint sensitivity, while electronic Clinical Outcome Assessment (eCOA) solutions are enabling patient, caregiver, and rater-friendly data capture solutions which deliver higher quality data across all stages of the disease.

In this fireside-chat-style webinar, Paul O’Donohoe, Senior Director of eCOA Product and Science from Medidata, and Dr. Kaycee Sink, MD, MAS, Chief Medical Officer at Cogstate, will explore how digital cognitive assessments and eCOA each contribute to improving Alzheimer’s trials, and how together they offer a powerful, complementary approach. From early-stage identification and intervention to studies involving patients with symptomatic disease, the session will examine how thoughtful digitization can enhance endpoint data quality, reduce participant and site burden, and provide deeper insight into patient experience.

Download the recording to discover what’s possible when scientific insight, clinical experience, and real-world examples come together, where thoughtful technology serves both the data and the people behind it.